Trillium Asset Management LLC Trims Stake in Johnson & Johnson (NYSE:JNJ)

Trillium Asset Management LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 3.3% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 15,012 shares of the company’s stock after selling 516 shares during the period. Trillium Asset Management LLC’s holdings in Johnson & Johnson were worth $2,338,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. State Street Corp boosted its stake in Johnson & Johnson by 1.1% in the second quarter. State Street Corp now owns 141,833,756 shares of the company’s stock valued at $23,476,323,000 after acquiring an additional 1,568,633 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its position in Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Geode Capital Management LLC lifted its position in Johnson & Johnson by 2.0% in the second quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock valued at $8,203,608,000 after purchasing an additional 990,298 shares during the period. Morgan Stanley lifted its position in Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the period. Finally, Capital International Investors lifted its position in Johnson & Johnson by 62.7% in the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after purchasing an additional 10,724,110 shares during the period. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JNJ. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Raymond James lifted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $167.00 to $180.00 in a research note on Friday, December 1st. Finally, TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $176.14.

Read Our Latest Stock Report on JNJ

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $156.76 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The firm’s 50-day simple moving average is $158.20 and its 200-day simple moving average is $158.73. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The firm has a market cap of $377.37 billion, a P/E ratio of 11.35, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The firm had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same period last year, the firm posted $2.35 EPS. The firm’s quarterly revenue was down 9.7% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s dividend payout ratio is 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.